FR09C0028I2 - MODIFIED GnRH ANTAGONISTS AT POSITIONS 5 AND 6 - Google Patents

MODIFIED GnRH ANTAGONISTS AT POSITIONS 5 AND 6

Info

Publication number
FR09C0028I2
FR09C0028I2 FR09C0028C FR09C0028C FR09C0028I2 FR 09C0028 I2 FR09C0028 I2 FR 09C0028I2 FR 09C0028 C FR09C0028 C FR 09C0028C FR 09C0028 C FR09C0028 C FR 09C0028C FR 09C0028 I2 FR09C0028 I2 FR 09C0028I2
Authority
FR
France
Prior art keywords
positions
gnrh antagonists
modified gnrh
modified
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0028C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25273352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0028(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring BV filed Critical Ferring BV
Publication of FR09C0028I1 publication Critical patent/FR09C0028I1/fr
Application granted granted Critical
Publication of FR09C0028I2 publication Critical patent/FR09C0028I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
FR09C0028C 1997-04-11 2009-07-15 MODIFIED GnRH ANTAGONISTS AT POSITIONS 5 AND 6 Active FR09C0028I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/837,042 US5925730A (en) 1997-04-11 1997-04-11 GnRH antagonists
PCT/US1998/007438 WO1998046634A1 (en) 1997-04-11 1998-04-13 GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6

Publications (2)

Publication Number Publication Date
FR09C0028I1 FR09C0028I1 (en) 2009-09-25
FR09C0028I2 true FR09C0028I2 (en) 2010-06-11

Family

ID=25273352

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0028C Active FR09C0028I2 (en) 1997-04-11 2009-07-15 MODIFIED GnRH ANTAGONISTS AT POSITIONS 5 AND 6

Country Status (37)

Country Link
US (2) US5925730A (en)
EP (1) EP1003774B1 (en)
JP (2) JP4249806B2 (en)
KR (1) KR100519421B1 (en)
CN (1) CN1230442C (en)
AR (1) AR011217A1 (en)
AT (1) ATE319736T1 (en)
AU (1) AU728642B2 (en)
BR (1) BR9808523B1 (en)
CA (1) CA2286190C (en)
CY (2) CY1108063T1 (en)
CZ (1) CZ299097B6 (en)
DE (2) DE122009000033I2 (en)
DK (1) DK1003774T3 (en)
EE (1) EE03974B1 (en)
ES (1) ES2260833T3 (en)
FR (1) FR09C0028I2 (en)
HK (1) HK1025104A1 (en)
HR (1) HRP980197B1 (en)
HU (1) HU224836B1 (en)
IL (1) IL132303A0 (en)
LU (1) LU91585I2 (en)
MY (1) MY114811A (en)
NL (1) NL300395I2 (en)
NO (2) NO324991B1 (en)
NZ (1) NZ500142A (en)
PL (1) PL194509B1 (en)
PT (1) PT1003774E (en)
RU (1) RU2199549C2 (en)
SI (1) SI1003774T1 (en)
SK (1) SK285381B6 (en)
TR (1) TR199902956T2 (en)
TW (1) TW505658B (en)
UA (1) UA58547C2 (en)
UY (1) UY24958A1 (en)
WO (1) WO1998046634A1 (en)
ZA (1) ZA983062B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5977302A (en) * 1997-11-20 1999-11-02 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of GnRH peptides
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
DE20321887U1 (en) 2003-11-10 2012-01-20 Allergan, Inc. Medicines comprising low doses of desmopressin
CN1878563A (en) 2003-11-10 2006-12-13 西摩·H·费恩 Pharmaceutical compositions including low dosages of desmopressin
CN101037472B (en) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 LHRH antagonist with low-histamine releasing function
KR101191322B1 (en) * 2006-04-07 2012-10-16 메리온 리서치 Ⅲ 리미티드 Solid oral dosage form containing an enhancer
TWI442932B (en) 2008-02-11 2014-07-01 Ferring Int Ct Sa Methods of treating prostate cancer with gnrh antagonist
TW200950799A (en) * 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of GnRH related compounds and processes of preparation
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
DK2421887T3 (en) * 2009-04-24 2015-07-27 Polypeptide Laboratories As A process for the preparation of degarelix
CN105663059A (en) * 2009-05-01 2016-06-15 辉凌公司 Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
RS55457B1 (en) 2010-10-27 2017-04-28 Ferring Bv Process for the manufacture of degarelix and its intermediates
WO2012088397A2 (en) 2010-12-22 2012-06-28 The Salk Institute For Biological Studies Cyclic crf antagonist peptides
JP2014501784A (en) 2011-01-07 2014-01-23 メリオン・リサーチ・Ｉｉｉ・リミテッド Pharmaceutical composition of iron for oral administration
JO3755B1 (en) 2011-01-26 2021-01-31 Ferring Bv Testosterone formulations
WO2013104745A1 (en) 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
RU2657444C2 (en) 2012-06-01 2018-06-13 Ферринг Б.В. Manufacture of degarelix
JP7211704B2 (en) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス A tablet containing a GLP-1 agonist and an enteric coating
US11168114B2 (en) 2015-12-17 2021-11-09 Fresenius Kabi iPSUM S.r.l Process for the manufacture of degarelix and its intermediates
CN107778355B (en) * 2016-08-25 2021-04-20 成都圣诺生物制药有限公司 Method for synthesizing cetrorelix
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
EP4004001A4 (en) 2019-07-29 2023-08-30 Sunshine Lake Pharma Co., Ltd. Substituted pyrimidinedione compounds and uses thereof
US11332495B2 (en) 2019-09-21 2022-05-17 RK Pharma Solutions LLC Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix
CN114456236A (en) * 2020-11-09 2022-05-10 深圳市健翔生物制药有限公司 Preparation method of degarelix acetylated impurities
WO2023072284A1 (en) 2021-11-01 2023-05-04 山东绿叶制药有限公司 Gonadotropin-releasing hormone antagonist, and preparation method therefor and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4508921A (en) * 1984-06-28 1985-04-02 Merck & Co., Inc. Process for preparation of alpha-alkyl amino acids
US4866160A (en) * 1985-04-09 1989-09-12 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5296468A (en) * 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
ES2052488T3 (en) * 1991-04-25 1997-01-01 Romano Deghenghi ANTAGONIST PEPTIDES OF THE LUTEINIZING HORMONE RELEASE HORMONE.
ES2164096T3 (en) * 1992-12-18 2002-02-16 Abbott Lab LHRH ANTAGONISTS UNDERSTANDING AMINOACIT REMAINS MODIFIED IN POSITION 5 AND 6.
IL108509A0 (en) * 1993-02-22 1994-05-30 Salk Inst For Biological Studi GnRH antagonist peptides
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists

Also Published As

Publication number Publication date
JP2005120101A (en) 2005-05-12
NO2009016I2 (en) 2014-08-25
NO324991B1 (en) 2008-01-14
PT1003774E (en) 2006-05-31
EE9900479A (en) 2000-06-15
AU6969898A (en) 1998-11-11
JP4249806B2 (en) 2009-04-08
HUP0002704A3 (en) 2003-08-28
US6214798B1 (en) 2001-04-10
NZ500142A (en) 2001-10-26
SI1003774T1 (en) 2006-08-31
AR011217A1 (en) 2000-08-02
DE122009000033I2 (en) 2011-07-21
US5925730A (en) 1999-07-20
CN1259959A (en) 2000-07-12
DE122009000033I1 (en) 2009-09-17
TR199902956T2 (en) 2000-08-21
CY2009008I1 (en) 2012-01-25
KR100519421B1 (en) 2005-10-06
SK285381B6 (en) 2006-12-07
CZ358699A3 (en) 2000-06-14
PL194509B1 (en) 2007-06-29
NL300395I2 (en) 2010-01-04
CN1230442C (en) 2005-12-07
HU224836B1 (en) 2006-03-28
DE69833751D1 (en) 2006-05-04
NO994906D0 (en) 1999-10-08
HRP980197A2 (en) 1999-02-28
UA58547C2 (en) 2003-08-15
KR20010006233A (en) 2001-01-26
HRP980197B1 (en) 2002-08-31
LU91585I2 (en) 2009-09-17
BR9808523B1 (en) 2010-02-09
MY114811A (en) 2003-01-31
BR9808523A (en) 2000-05-23
IL132303A0 (en) 2001-03-19
ZA983062B (en) 1998-10-20
AU728642B2 (en) 2001-01-11
NO994906L (en) 1999-12-13
CY2009008I2 (en) 2012-01-25
JP3645255B1 (en) 2005-05-11
RU2199549C2 (en) 2003-02-27
NL300395I1 (en) 2009-09-01
CY1108063T1 (en) 2012-01-25
CA2286190A1 (en) 1998-10-22
UY24958A1 (en) 2001-03-16
EP1003774A1 (en) 2000-05-31
TW505658B (en) 2002-10-11
CZ299097B6 (en) 2008-04-23
HUP0002704A2 (en) 2000-12-28
ATE319736T1 (en) 2006-03-15
DE69833751T2 (en) 2006-11-09
ES2260833T3 (en) 2006-11-01
FR09C0028I1 (en) 2009-09-25
NO2009016I1 (en) 2009-08-10
JP2001523229A (en) 2001-11-20
DK1003774T3 (en) 2006-07-03
SK139699A3 (en) 2000-11-07
HK1025104A1 (en) 2000-11-03
WO1998046634A1 (en) 1998-10-22
CA2286190C (en) 2007-01-09
EP1003774B1 (en) 2006-03-08
EE03974B1 (en) 2003-02-17
PL336213A1 (en) 2000-06-05

Similar Documents

Publication Publication Date Title
FR09C0028I2 (en) MODIFIED GnRH ANTAGONISTS AT POSITIONS 5 AND 6
DE59713038D1 (en) streptavidin muteins
DE69823876D1 (en) INDUCTIVE COMPONENT AND INDUCTIVE COMPONENT ARRANGEMENT
ID18003A (en) MUSCARINIC ANTAGONISTS
DE69735349D1 (en) TRIANGLE DIGITIZED TRANSISTOR TRANSISTOR
PT805813E (en) TRASTERIC VASOPRESSIN ANTAGONISTS
DE59608953D1 (en) ball joint
DE59701856D1 (en) BALL JOINT
ID24669A (en) DOLASTATIN 15
ATE227724T1 (en) MUSCARINAGONISTS AND ANTAGONISTS
DE59607339D1 (en) Ball joint
DE29704875U1 (en) Joystick arrangement
NO992059D0 (en) 2 metoksyfenylpiperazinderivater
PT811593E (en) INSECTICID AND ACARICID AGENTS 1,4-DIARY-2-FLUOR-2-BUTENE
DE29616350U1 (en) Ball joint
EE9800165A (en) Enhanced LHRH antagonists
DE29612455U1 (en) Ball joint
DE69709700T2 (en) CONTRAST AGENTS
KR970702876A (en) Neurokinine (tachykinine) antagonists
DE29704732U1 (en) Ball joint arrangement
KR970006948U (en) Study timetable
BR9404585A (en) Tin and tin body
BR9602431A (en) Joint depressor and regulator
DE29516777U1 (en) Breakdown aid ball
DE29616653U1 (en) Latex spray